Cargando…

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report

BACKGROUND: CFTR modulator therapy with ivacaftor is a treatment option for Cystic Fibrosis (CF) patients with at least one copy of a R117H-7T mutation in the CFTR gene. Desirable effects of this therapy are improvement of lung function, decrease in exacerbation rate, normalization or reduction of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welsner, Matthias, Straßburg, Svenja, Taube, Christian, Sutharsan, Sivagurunathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458608/ https://www.ncbi.nlm.nih.gov/pubmed/30975115 http://dx.doi.org/10.1186/s12890-019-0840-8

Ejemplares similares

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)

How personality influences health outcomes and quality of life in adult patients with cystic fibrosis
por: Niehammer, Ute, et al.
Publicado: (2023)

Cough suppression and HRQoL in adult people with cystic fibrosis: an unexplored correlation
por: Niehammer, Ute, et al.
Publicado: (2022)

Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
por: Straßburg, Svenja, et al.
Publicado: (2022)

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
por: Olivier, Margarete, et al.
Publicado: (2023)

Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis
por: Welsner, Matthias, et al.
Publicado: (2022)

Changes in Clinical Markers During A Short-Term Transfer Program of Adult Cystic Fibrosis Patients from Pediatric to Adult Care
por: Welsner, Matthias, et al.
Publicado: (2019)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
por: Kuek, Stephanie L., et al.
Publicado: (2022)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

P079 Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation
por: Vincken, S., et al.
Publicado: (2022)

Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program
por: Welsner, Matthias, et al.
Publicado: (2021)

Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis
por: Dillenhoefer, Stefanie, et al.
Publicado: (2022)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Effects of a Long-Term Monitored Exercise Program on Aerobic Fitness in a Small Group of Children with Cystic Fibrosis
por: Gruber, Wolfgang, et al.
Publicado: (2022)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
por: Salvatore, Donatello, et al.
Publicado: (2021)

Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy
por: Gruber, Wolfgang, et al.
Publicado: (2023)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins
por: Fischer, Sebastian, et al.
Publicado: (2021)

Species-Specific Interferon-Gamma Release Assay for the Diagnosis of Mycobacterium abscessus Complex Infection
por: Steindor, Mathis, et al.
Publicado: (2021)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation
por: Burghard, M (Marcella), et al.
Publicado: (2020)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
por: Shteinberg, Michal, et al.
Publicado: (2017)

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
por: Mall, Marcus A., et al.
Publicado: (2022)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Twinning: Coronary Artery Disease in Monozygotic Twins
por: Smith, Megan C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l6h64vk8eo85jon5q12jst5imh